Lakefront Biotherapeutics American Depositary Shares
LKFT
116 hedge funds and large institutions have $452M invested in Lakefront Biotherapeutics American Depositary Shares in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 31 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 31
3% less funds holding
Funds holding: 119 → 116 (-3)
4.38% less ownership
Funds ownership: 11.36% → 6.98% (-4.4%)
57% less capital invested
Capital invested by funds: $1.05B → $452M (-$599M)
69% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $44.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$120M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$31.7M |
| 3 |
SC
Sessa Capital
New York
|
+$10M |
| 4 |
Morgan Stanley
New York
|
+$9.46M |
| 5 |
Millennium Management
New York
|
+$9.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$324M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$154M |
| 3 |
Bessemer Group
Woodbridge,
New Jersey
|
-$40.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.5M |
LKFT Hedge Fund Activity: Q4 2020 in Review
116 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2020, worth a combined $452M — down 57% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of LKFT and 29 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 41 added.
The largest buyer was Capital International Investors, adding an estimated $120M. The largest seller was Sands Capital Management, exiting entirely with an estimated $324M sold.
- 116 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2020, down from 119 in Q3 2020.
- Funds reported $452M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2020, down 57% quarter-over-quarter.
- 29 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2020 and 31 closed out, a net change of -2 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2020 was Capital International Investors, an estimated $120M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2020 was Sands Capital Management, an estimated $324M sold.
Based on aggregated 13F filings for Q4 2020.